CYP8B1 and neoplasm: The mean survival in patients with tumours showing negative/weak CYP8B1 immunoreactivity (n=371) was 126 months (95% CI 115-136) compared to 91 months (95% CI 82-99) in patients with tumours showing moderate/strong immunoreactivity (n=251).